S5326

SB-271046A

≥98% (HPLC)

• 别名: 5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzo-thiophenesulfonamide hydrochloride
• 经验公式（希尔记法）: C₂₀H₂₂ClN₃O₃S₂ · HCl
• CAS号: 209481-24-3
• 分子量: 488.45
• MDL號碼: MFCD10565914
• 分類程式碼代碼: 12352200
• PubChem物質ID: 329824453
• NACRES: NA.77

属性

• 化驗: ≥98% (HPLC)
• 形狀: powder
• 溶解度: DMSO: >20 mg/mL
• 起源: GlaxoSmithKline
• 儲存溫度: 2-8°C
• SMILES 字串: Cl.COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N4CCNCC4
• InChI: 1S/C20H22ClN3O3S2.ClH/c1-13-16-11-14(21)3-6-19(16)28-20(13)29(25,26)23-15-4-5-18(27-2)17(12-15)24-9-7-22-8-10-24;/h3-6,11-12,22-23H,7-10H2,1-2H3;1H
• InChI 密鑰: RMXZRJYGJMSDQK-UHFFFAOYSA-N

说明

生化／生理作用

The first potent and selective 5-HT₆ antagonist. Training in cognitive tasks, as well as administration SB-271046, induces an increase in pERK1/2 and pCREB1 levels, while CREB2 levels are significantly reduced; cognition-enhancing properties of SB-271046 are attributed to the effect on pERK1/2, not pCREB1/2. SB-271046 reverses MK-801-induced, but not scopolamine-induced, learning impairments. However, with coadministration of galanthamine, both types of learning impairments were ameliorated.

特點和優勢

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

安全信息

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: nwg
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable